title: Incidence of neutropenia during treatment of bone-related infections with piperacillin-tazobactam.
abstract: Of 41 patients with bone-related infections who were treated for > or =10 days with piperacillin-tazobactam, 14 (34%) developed neutropenia. Cumulative doses of piperacillin administered to neutropenic patients were higher than those administered to nonneutropenic ones (330 vs. 237 g; P=.008), and an inverse correlation was detected between the absolute neutrophil count at the end of treatment and the cumulative dose of piperacillin (r=-0.47, P=.002). Moreover, the incidence of piperacillin-tazobactam-induced neutropenia increased with an increase in the cumulative dose of piperacillin: 0% of patients in the first quartile of cumulative piperacillin doses, 33.3% in the second quartile, 40% in the third quartile, and 66.7% in the fourth quartile.
authors: Internal Medicine, Sierrallana Hospital, Torrelavega, Spain. gpf@mundivia.es
authors: F G
authors: FG
authors: Peralta
authors: M B
authors: MB
authors: Sánchez
authors: M P
authors: MP
authors: Roíz
authors: M A
authors: MA
authors: Pena
authors: M A
authors: MA
authors: Tejero
authors: R
authors: R
authors: Arjona
mesh_terms: D000367:Age Factors; D000368:Aged; D004359:Drug Therapy, Combination / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005334:Fever / Q000209:etiology; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced* / Q000453:epidemiology; D010019:Osteomyelitis / Q000150:complications / Q000188:drug therapy; D010397:Penicillanic Acid / Q000009:adverse effects* / Q000031:analogs & derivatives / Q000627:therapeutic use; D010878:Piperacillin / Q000009:adverse effects* / Q000627:therapeutic use; D000077725:Piperacillin, Tazobactam Drug Combination
chemical_list: D000077725:Piperacillin, Tazobactam Drug Combination; D010397:Penicillanic Acid; D010878:Piperacillin